Allworth Financial LP Sells 1,220 Shares of Becton, Dickinson and Company (NYSE:BDX)

Allworth Financial LP decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,323 shares of the medical instruments supplier’s stock after selling 1,220 shares during the period. Allworth Financial LP’s holdings in Becton, Dickinson and Company were worth $3,249,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BDX. Harbour Investments Inc. increased its holdings in shares of Becton, Dickinson and Company by 2.9% during the 2nd quarter. Harbour Investments Inc. now owns 1,331 shares of the medical instruments supplier’s stock worth $351,000 after acquiring an additional 38 shares during the last quarter. Jeppson Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after purchasing an additional 40 shares during the period. Optimum Investment Advisors boosted its stake in Becton, Dickinson and Company by 35.6% in the 3rd quarter. Optimum Investment Advisors now owns 160 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 42 shares during the period. CX Institutional boosted its stake in Becton, Dickinson and Company by 3.0% in the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock valued at $385,000 after purchasing an additional 43 shares during the period. Finally, U.S. Capital Wealth Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock valued at $339,000 after acquiring an additional 43 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $246.17 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $71.12 billion, a PE ratio of 58.33, a P/E/G ratio of 2.03 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $229.85 and a 12 month high of $287.32. The stock has a 50-day moving average price of $240.40 and a two-hundred day moving average price of $244.07.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.98 earnings per share. Analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were issued a $0.95 dividend. The ex-dividend date was Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a yield of 1.54%. Becton, Dickinson and Company’s payout ratio is currently 90.05%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BDX. Barclays upped their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Raymond James upped their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.